Zero Revenue, $1M Net Loss for Kraig Biocraft in Q1
KBLB sits 97% above its 52-week low of $0.072 on light trading volume (0.3× avg).
Summary
Kraig Biocraft Laboratories reported Q1 2026 financial results with zero revenue and a net loss of $1 million, a significant widening from a $600,000 loss in the prior year's quarter. This poor financial performance underscores the company's pre-revenue status and increasing operational burn rate. The results are particularly concerning given the recent SEC filings on May 14th, which disclosed the registration of over 306 million shares for resale, potentially diluting existing shareholders by 27.5%. While the company recently commissioned a new spider silk production center, the Q1 results indicate that commercialization and revenue generation remain distant. Traders will be closely monitoring future reports for any signs of revenue growth or improved cost management, especially in light of ongoing capital needs.
At the time of this announcement, KBLB was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $156M. The 52-week trading range was $0.07 to $0.16. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.